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Introduction
Snus is a form of smokeless tobacco that has been used for decades in the Scandinavian countries. It is consumed by placing a portion under the upper lip in front of the gingiva and is increasingly popular amongst young people (1) . The snus market is rapidly spreading worldwide and snus was recently launched in the US (2, 3) . Previous studies have estimated that around 22% of men and 4% of women are using snus, and the prevalence of women using snus is increasing (2, 4, 5) .
The exposure time of snus is higher than for smoking; with an average duration time of 60−70 minutes per portion, giving twice as large the amount of nicotine (6, 7) . It consists of tobacco, water, sodium chloride, sodium carbonate, humectants, and flavoring agents, and large amounts of these contents are swallowed into the digestive tract (1, 8, 9) .
Gastroesophageal reflux disease (GERD) is caused by abnormal backflow of gastric contents into the esophagus, producing symptoms and mucosal damage (10, 11) . The main symptoms of GERD are heartburn and regurgitation, and the prevalence of GERD in Western adult populations is up to 30% (12, 13) . GERD is associated with reduced health related quality of life (14) and work productivity (15) , and an increased risk of esophageal adenocarcinoma (16) . Genetic predispositions and lifestyle factors, including obesity and tobacco smoking, increase the risk of GERD (17) . Due to the existing evidence of tobacco smoking as a causal factor for GERD, snus has been proposed as a similar risk factor for the development of GERD (17) (18) (19) (20) . A study by Aro et al. found an association between snus use and histological changes in the esophagus associated with GERD (basal cell hyperplasia and elongation of papillae) (21) .
In general, the documentation of the health effects of snus is sparse, and the continuous product development of snus and changes in its ingredients makes interpretation of old research troublesome (9) .
The aim of this study was to investigate if snus is a risk factor for gastroesophageal reflux symptoms (GERS), using a large population-based study from Norway.
Methods
Material
The Nord-Trøndelag health study (HUNT) is an on-going population based cohort study.
Nord-Trøndelag is a county in the central part of Norway with about 135,000 inhabitants (in 2014). All residents above 20 years of age were asked to participate in three health surveys; HUNT1 (1984 HUNT1 ( -1986 , HUNT2 (1995 HUNT2 ( -1997 , and HUNT3 (2006-2008) (22) . In HUNT1, 77,212 individuals (89% of the total population) participated and the corresponding numbers were 65,237 (70%) and 50,807 (54%) in HUNT2 and HUNT3, respectively. This makes HUNT the largest population based study in Norway, and also one of the largest internationally.
Data on health-related items were gathered through self-reported questionnaires, clinical examinations, and blood samples of the participants.
As snus use was assessed in HUNT3 only, the present study is based on HUNT3. In addition, a short questionnaire for non-participants (the QNP) sent out in 2009 to those who did not participate in HUNT3 was also included (n=7,591).
Assessment of snus use
In HUNT3 and the QNP, the participants were asked, "Do you use, or have you previously used snus?" with the possible answers "no, never", "yes, but I quit", "yes, occasionally", and "yes, daily".
For those "ever" using snus, HUNT3 included four additional questions regarding snus. The participants were asked about their consumption of snus per month, at what age they started using snus, their motivation to start using snus, and what type of tobacco they started with. These additional questions were not included in the QNP.
Assessment of gastroesophageal reflux symptoms
GERS was assessed with the question "To what degree have you had acid regurgitation or heartburn during the last 12 months" with the alternatives "never", "a little", or "much" complaint. Previous validations of this question found that 95−98% of those reporting much complaint had symptoms at least weekly, thereby fulfilling the Montreal criteria for GERD (11, 23, 24) .
Those reporting much complaint were defined as the case group ("Severe GERS"), while those reporting never complaint were defined as controls ("No GERS"). Those reporting a little complaint were excluded from our analysis.
Assessment of co-variables
In the present study age, sex, tobacco smoking, body mass index (BMI), and physical exercise were taken into consideration as potential confounders.
The participants were asked, "Do you smoke?" with the alternatives: "no, I have never smoked", "no, I quit smoking", "yes, occasionally", or "yes, daily". Physical exercise was assessed by the question "How often do you exercise?" with the options "less than once a week", "once a week", "2−3 times a week", or "nearly every day", and further categorized into ≥ or < weekly, based on the self-reported frequency.
Statistical analysis
The risk of GERS among snus users compared to not snus users in HUNT3/QNP was estimated using multivariable logistic regression, reporting odds ratios (ORs) with 95% confidence intervals (CIs). We present crude ORs, age and sex adjusted ORs, and fully adjusted ORs, including adjustments for age, sex, smoking status, BMI, and physical exercise.
The additional questions regarding snus were used in separate sub-analyses. As these additional questions only were included in HUNT3, the participants in QNP were excluded in these sub-analyses.
We tested the main model for interactions, and based on these results we performed analyses stratified by age and smoking status. 
Results
In total, 58,634 individuals participated in HUNT3 and the QNP and 2,993 (5.1%) had severe GERS (cases) and 26,610 (45.4%) had no GERS (controls; Table I ).
Characteristics
The cases were older than the controls (mean age 54.3 and 50.1 years, respectively). The participation rate was higher among women than men, but the proportion of cases was higher among men than women (11.8% and 10.8%, respectively).
Daily snus use was less common among cases than controls (5.4% and 7.3%, respectively).
On the other hand, previous snus use and occasional snus use were more common among cases. The cases using snus were older than the controls using snus (mean age 43.3 and 41.8 years, respectively). The mean age at the start of their snus use was similar for both groups.
Snus consumption (boxes per month) was higher for cases than for controls. More cases than controls started using snus to quit or cut down on smoking, and more cases than controls started with cigarettes first. Compared to the controls, more cases were current or previous tobacco smokers, had a higher BMI, and exercised less frequently.
Associations
Compared to never snus users, daily snus users had a reduced risk of severe GERS; fully adjusted OR 0.77 (95% CI 0.64−0.93; Table II ). However, previous snus users had increased risk of severe GERS; fully adjusted OR 1.20 (1.00−1.46). Moreover, those using <2 boxes per month had increased risk of severe GERS; fully adjusted OR 1.41 (1.02−1.96), while there was no statistically significant association between snus use and use of ≥2 boxes of snus per month.
There was no association between age when starting using snus and severe GERS (Table III) .
Compared to those reporting no specific motivation to start using snus, those snus users who started using snus to quit or cut down on smoking had an increased risk of severe GERS; (Table IV) .
Discussion
This large population-based observational study showed that daily snus users had a reduced risk of severe GERS compared with not snus users. However, previous snus users and subgroups of snus users had an increased risk of severe GERS: those consuming <2 boxes of snus per month, snus users who started with both snus and cigarettes or cigarettes alone, snus users who started using snus to quit or cut down cigarette smoking, and snus users <30 years of age. In snus users the risk of severe GERS was reduced with increasing age.
The large population-based study design facilitates subgroup analyses and reduces the risk of selection bias. However, it is known that those participating in population-based studies have higher socioeconomic status compared to those not participating. As diseases and health related risk factors are often related to socioeconomic status, this makes selection bias possible (25, 26) and might weaken the external validity of the results. Except for lower average income and education, and the lack of a large city, the population in Nord-Trøndelag is representative of the Norwegian population at large (27). The extensive questionnaires used in HUNT also allowed adjustments for possible confounders of the association between snus use and GERS. Alcohol use is associated with snus use and some studies have also found an association between alcohol use and reflux, while other studies have not found any association (28) . In our previous studies on GERS using the HUNT material, alcohol use was not associated with reflux (17, 20) and, thus, we have not included alcohol use as a possible confounder in this study. All questionnaires used in this study were self-reported. Even if self-reported questionnaires are validated (29), we cannot exclude possible information bias in our study (30) .
In HUNT, more men than women were using snus, current snus users were younger than not snus users, snus use was associated with lower education, higher alcohol consumption, and less physical exercise, and smoking rates were lower among daily snus users (2) .
According to the Montreal definition, GERD is "a condition that develops when reflux of stomach contents causes troublesome symptoms and/or complications. (…) In population-based studies, mild symptoms occurring two or more days a week, or moderate/severe symptoms occurring more than one day a week, are often considered troublesome by patients" (11) . The HUNT study was initiated before the Montreal consensus and did not use this definition. However, the question used in HUNT has been validated and these validations have shown that participants reporting severe complaints in HUNT have at least weekly symptoms (23, 24) .
We have no information available on whether the participants were taking anti-reflux medications. This could have reduced the proportion of participants reporting GERS. In addition, participants with GERS may also have developed Barrett's esophagus which has the potential to reduce symptoms. However, only a small percentage of the participants are expected to develop Barrett's so this should not have influenced the overall results.
In this study we hypothesized that snus use would increase the risk of GERS. However, the overall result was that snus use seems to protect against GERS. We believe this could be explained by reverse causality, meaning that those with severe GERS because of snus stop their exposure to snus (20) . The results of the subgroup analyses support this assumption.
Previous snus users developing GERS may have quit using snus as a result of snus inducing GERS. This is also supported by the declining trend from high risk of GERS among young snus users to low risk with increasing age. This is the opposite of the trend in prevalence of GERS seen in the total population (24) . If reverse causality is the explanation, our results will wrongfully suggest that snus has a protective effect against GERS and persons with a lower predisposition of developing GERS will continue using snus.
If snus increases the risk of GERS, one would presume an increasing prevalence with increasing doses; a dose-response relationship. However, in this study we found that those using <2 boxes per month were more likely to have GERS than those with a higher consumption. Again, if our theory of reverse causality is true, this may be explained by GERS inducing a reduced exposure to snus. One could argue that GERS induced by snus should disappear when quitting snus. However, individuals with GERS probably have several risk factors, including a genetic predisposition, but snus is maybe one factor which is recognizable as a trigger of GERS and probably easier to deal with than other risk factors. So, even if snus is stopped and this has an effect on GERS, it is unlikely that this would make all the complaints disappear. A previous study on this topic, the Kalixanda study, found histological changes associated with GERD in the mucosa of snus users, supporting an increased risk of GERS with snus use (21) . However, the study did not find any link between snus consumption and GERS. If our findings are not caused by reverse causality, snus may indeed have a protective effect against GERS and this makes our results highly controversial.
In this case, the protective effect of snus could be explained by increased saliva section in snus users (31), the relatively high pH (approximately 8.5) (8, 32) or other unknown effects of the snus contents on the esophageal or gastric mucosa, e.g. creating a barrier effect or reducing acid secretion, respectively. However, these protective effects would likely affect all age groups and cannot explain the reduced risk of GERS exclusively seen in the older snus users.
In conclusion, this study found that daily snus users overall had a reduced risk of GERS.
However, subgroups of snus users had an increased risk of GERS and we propose that the overall result could be due to reverse causality and that snus use actually increases the risk of GERS. Further research is needed to conclude whether snus use is a risk factor for the development of GERS. A study combining a detailed questionnaire on reflux symptoms, antireflux medication and risk factors with objective investigations with endoscopy and pHmeasurements may increase the evidence on this topic.
In 2017-2018, HUNT4 will be conducted and the same population as in HUNT3 will be reinvited to participate. This provides an excellent opportunity to follow snus users prospectively and to investigate further whether the reduced risk of GERS seen in this study is related to reverse causality or not. 
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